97 results about "Fusobacterium nucleatum" patented technology

The invention discloses lactobacillus rhamnosus. A strain (lactobacillus rhamnosus) LR863 is preserved in China General Microbiological Culture Collection Center (CGMCC) and the preservation number isCGMCC No. 14410. The lactobacillus rhamnosus disclosed by the invention has remarkable bacterium-inhibition and sterilization effects on oral pathogenic microorganisms including streptococcus mutans,streptococcus gordonii, porphyromonas gingivalis, fusobacterium nucleatum, actinobacillus actinomycetemcomitans and the like, and has the effects of reducing formation of dental plaque and reducing occurrence and development of oral diseases including tooth decay, periodontitis and the like. A lactobacillus rhamnosus preparation disclosed by the invention can comprise viable bacterium thalli of the lactobacillus rhamnosus, dead bacterium thalli of the lactobacillus rhamnosus, metabolic products of the lactobacillus rhamnosus and intracellular extract, is an oral probiotics preparation which has wide application and a remarkable effect, and can be widely used as an additive of liquid-state foods, solid-state foods, colloidal foods, oral hygiene products and oral treatment drugs.

The invention discloses tyrosine phenol-lyase (TPL) mutant of fusobacterium nucleatum, a gene, a carrier, an engineered bacteria strain, and applications of the TPL mutant of fusobacterium nucleatum in synthetizing levodopa. Compared with the wild type, the TPL mutant of fusobacterium nucleatum provided by the invention has the more excellent catalytic performance. The accumulated concentration in synthesizing levodopa of the TPL mutant of fusobacterium nucleatum achieves 140g / L or above, compared with that of the wild type, the accumulated concentration is improved by 17-25 %, and the optical purity is greater than 99.5%; the conversion rate of the substrate, namely, catechol achieves 99.8% or above, and compared with that of the wild type, the conversion rate is improved by 15-20 %.

Methods and materials for detecting colorectal cancer using DNA markers from human stool. More specifically, methods and materials for quantification of FNN bacteria DNA per unit stool weight as a molecular marker for CRC diagnosis.

The invention relates to a method for calculating a flora balanced relation index in an individual excrement sample, and an application of the method in screening, diagnosis or auxiliary diagnosis incolorectal cancer (CRC). By extracting bacteria in excrement during DNA sequencing, the types and quantity characteristics of the bacteria can be obtained, and a CRC diagnosis by taking quantity ratiocharacteristic of a plurality of bacteria as a base is carried out. Compared with the methods used in clinical diagnosis or noninvasive screening of CRC with an applied patent, the method is completely noninvasive, and can realize accurate diagnosis of CRC. The analysis result displays that a ratio of fusobacterium nucleatum Fn to bifidobacteria Bb quantity (Fn / Bb) has high susceptibility and specificity on CRC screening, which can respectively reach 84.6% and 92.3% (AUC=0.911). the ratio of fusobacterium nucleatum Fn to clostridium leptum Fp (Fn / Fp) quantity is combined to increase the diagnosis value on CRC, and the Area Under Curve (AUC) of a subject work characteristic curve can reach 0.943. In addition, combination of Fn / Bb and Fn / Fp quantity ratio for screening I-stage CRC has 60% of specificity and 90% of sensitivity.

The invention discloses a nucleic acid combination for detecting Fusobacterium nucleatum in night soil, and applications and kits thereof, and belongs to the technical field of biomedical examination. The nucleic acid combination for detecting Fusobacterium nucleatum in night soil can specifically detect the Fusobacterium nucleatum. The nucleic acid combination is used to prepare a kit for detecting Fusobacterium nucleatum in night soil and a kit for detecting cancer. The kits effectively improve the detection precision, can be conveniently and fast applied to detect the Fusobacterium nucleatum, and have high sensitivity and specificity. A technologic method provided by the invention can be used to conveniently extract Fusobacterium nucleatum genome from the night soil, and has the advantages of quantitative detection of the Fusobacterium nucleatum, simplicity in operation, and facilitation of promotion and application.

The invention discloses supramolecular hydrogel and also discloses a preparation method and application of the supramolecular hydrogel. The supramolecular hydrogel disclosed by the invention is prepared from a 2-deoxy-2-fluoro-guanosine analogue and silver ions. The silver-ion supramolecular antibacterial hydrogel provided by the invention has the advantages of simplicity in preparation, low toxicity, good biocompatibility, excellent stable performance and the like; the silver ions can be effectively alleviated and the antibacterial activity is good; especially, the silver-ion supramolecular antibacterial hydrogel has relatively high antibacterial activity on methicillin-resistant staphylococcus aureus ATCC25923 and ATCC33591, and fusobacterium nucleatum; the silver-ion supramolecular antibacterial hydrogel is prepared into an antibacterial material and has a relatively good application prospect.

The invention discloses an IgY antibody preparation having mixed specificity for resistance to streptococcus mutans and streptococcus sobrinus. The IgY antibody preparation is prepared by mixing 10-70 parts by weight of streptococcus mutans bacteria and bacteria pieces and 30-90 parts by weight of streptococcus sobrinus bacteria and bacteria pieces into an antigen via laying hens. The invention also discloses a preparation method of the IgY antibody preparation having the mixed specificity for resistance to the streptococcus mutans and the streptococcus sobrinus, and a toothpaste which contains the IgY antibody preparation having the mixed specificity for resistance to the streptococcus mutans and the streptococcus sobrinus and the IgY antibody preparation having the mixed specificity for resistance to the anti-porphyromonas gingivalis and the fusobacterium nucleatum and is used for preventing saprodontia, gingivitis and halitosis thereof. The toothpaste used for preventing saprodontia, gingivitis, periodontitis and halitosis halitosis thereof has obvious effects for preventing saprodontia, gingivitis, periodontitis and halitosis bacteria thereof.

The invention discloses IgY mouthwash prepared by anti-porphyromonas gingivalis and an IgY antibody with fusobacterium nucleatum specificity, which is used for preventing gingivitis and gingivitis ozostomia. The IgY mouthwash comprises an IgY preparation for resisting periodontal pathogens and basic mouthwash materials, wherein the IgY preparation for resisting periodontal pathogens is prepared by raw materials according to the following mass percent accounting for the total mass of toothpaste: 0.01%-0.5% of anti-porphyromonas gingivalis and IgY antibody preparation with fusobacterium nucleatum specificity, 0.01-2.0% of chlorhexidine, 1.0-30.0% of glycerol, and 0.1-2.0% of polyvinylpyrrolidone, wherein a protective preparation of the anti-porphyromonas gingivalis and the IgY antibody preparation with fusobacterium nucleatum specificity is prepared by the chlorhexidine, the glycerol, and the polyvinylpyrrolidone. The IgY mouthwash which is disclosed by the invention and is used for treating and preventing gingivitis and ozostomia has an obvious effect on treating and preventing the gingivitis and the ozostomia.

The application provides a lactobacillus paracasei PC-01 isolated from sour yak milk in Longren Township, Dangxiong County, Lhasa, Tibet, wherein the microbial preservation number of the lactobacillus paracasei PC-01 is CGMCC No.17537. The Lactobacillus paracasei PC-01 can improve oral health flora imbalance, has probiotics with better acid tolerance and bile salt tolerance, has probiotic characteristics, can be directly taken as a preparation for improving oral microecological environment, or as a raw material to prepare a microbial antagonist for pathological states in oral cavity, wherein the pathological state microorganisms comprise at least one of streptococcus mutans, Porphyromonas gingivalis, Treponema denticola, Genus Prevotella and Fusobacterium nucleatum.

The invention discloses an anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. According to the preparation, 10-70 parts by weight of porphyromonas gingivalis thalli and thalli fragments, and 30-90 parts by weight of fusobacterium nucleatum thalli and thalli fragments are compounded into an antigen to immune an egg laying hen. The invention also discloses the specific preparation method of the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation, and toothpaste containing the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. By the IgY toothpaste which is used for treating and preventing gingivitis and ozostomia has obvious effects in preventing and treating the gingivitis and the ozostomia.

The invention provides lactobacillus plantarum SD26 as well as a product and application thereof, and relates to the field of microorganisms. The lactobacillus plantarum SD26 provided by the inventionhas a preservation number of CGMCC No.19328, is derived from pickled vegetables, has an obvious inhibiting effect on oral pathogenic bacteria including streptococcus mutans, candida albicans, fusobacterium nucleatum and porphyromonas gingivalis and food-borne pathogenic bacteria including salmonella typhimurium, escherichia coli, staphylococcus aureus and listeria monocytogenes, and has good application potential in the aspects of prevention and treatment of the oral pathogenic bacteria and the food-borne pathogenic bacteria.

The invention provides a fusobacterium nucleatum subsp.vincentii strain THCT14A3 for intestinal tract separation. The classification designation is Fusobacterium nucleatum subsp.vincentii, the preservation number is CCTCC NO:M 2019363, the preservation date is May 17th, 2019, and the preservation unit is China Center for Type Culture Collection. The 16SrRNA gene sequence of the strain is as shownin SEQID NO:1. The invention further provides a specific DNA sequence for identifying the fusobacterium nucleatum subsp.vincentii and a primer sequence corresponding to the specific DNA sequences. Thecolorectal cancer cell line and THCT14A3 co-culture result show that the THCT14A3 can significantly promote colorectal cancer cell proliferation. Therefore, the THCT14A3 provided by the invention canfacilitate micro-ecology research of intestinal tracts suffering from colorectal cancer.

The invention provides a Fusobacterium nucleatum subsp. animalis strain THCT6b3 separated from human intestines. A 16SrRNA gene sequence of the strain is shown in SEQ ID NO:1. The classification nameof the strain is Fusobacterium nucleatum subsp. animalis and collected on May 17, 2019 with the collection number of CCTCC NO:M 2019363 in the China Center for Type Culture Collection. The invention further provides application of the strain in detection of Fusobacterium nucleatum. A PCR-based molecular identification method for Fusobacterium nucleatum subsp. animalis is established for the firsttime. The strain can promote disclosing of composition and sources of the Fusobacterium nucleatum in intestines of colorectal cancer patients, and contributes to analysis of molecular epidemiologic characteristics of the Fusobacterium nucleatum.

The invention discloses primer group information of fusobacterium nucleatum, a quantitative PCR (Polymerase Chain Reaction) detection method and application of primer group and method. According to a16S rRNA (ribosomal Ribonucleic Acid) nucleotide sequence and a BLAST (Basic Local Alignment Search Tool) function of bacteria in an NCBI (National Center of Biotechnology Information) database, a fusobacterium nucleatum related primer and V3 to V4 primers are designed according to primer design software Primer Primer 5, and the primers are identified. Genome information of total bacteria is extracted from an excrement sample; the qPCR (quantitative Polymerase Chain Reaction) is carried out through utilizing the primers and the relative content of the fusobacterium nucleatum is calculated andobtained. The detection method is used as a principle and an intestinal micro-ecological detection kit is prepared by utilizing the fusobacterium nucleatum primer. A kit is used for carrying out actual detection and a result shows that the content of the fusobacterium nucleatum in the excrement samples of an intestinal micro-ecological patient and a patient with intestinal cancer is remarkably different from that of normal people. A specific primer of the fusobacterium nucleatum, a rapid and accurate detection method and research and development of an intestinal micro-ecological kit provide methods for knowing the distribution of an intestinal micro-ecology and predicating and primarily screening diseases.

The invention discloses a colorectal cancer auxiliary diagnosis kit for fecal nucleic acid detection and a use method of the colorectal cancer auxiliary diagnosis kit. The kit comprises a KRAS gene mutation detection reagent, a fusobacterium nucleatum detection reagent, a DNA sulfite conversion reagent and a Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection reagent. The use method comprises the following steps: collecting an excrement sample, and then completing DNA purification, KRAS gene mutation detection, fusobacterium nucleatum abundance detection and Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection of the sample by using reagents in the kit; and calculating the obtained data through a logistic regression model, and performing result evaluation and analysis. The colorectal cancer detection sensitivity reaches 89% or above, the specificity reaches 94% or so, high-sensitivity and high-specificity colorectal cancer detection can be achieved, and doctors can be helped to guide follow-up treatment medication of patients.

The invention relates to the technical field of microorganisms, and discloses lactobacillus plantarum for preventing and / or treating periodontitis as well as a culture, preparation and application of the lactobacillus plantarum. The name of the lactobacillus plantarum is Lactobacillus plantarum CCFM1137, the lactobacillus plantarum is preserved in Guangdong Microbial Culture Collection Center on the 5th floor of the Building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou on August 1, 2020, and the preservation number is GDMCC No: 61114. The lactobacillus plantarum can be used for inhibiting the formation of a mixed bacterium biological membrane of porphyromonas gingivalis, prevotella intermedia and fusobacterium nucleatum; the content of inflammatory factors in a periodontitis cell model can be reduced; the expression quantity of transmembrane transport protein in a periodontitis cell model can be increased; and the lactobacillus plantarumcan be used for preventing and / or treating oral diseases and inhibiting prevotella intermedia, porphyromonas gingivalis and / or fusobacterium nucleatum.

The invention provides a fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from human rectal cancer tumor tissue. A classification name is Fusobacterium nucleatum subsp.animalis THCT5A4,a preservation number of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is CCTCC NO: M 2019366, the preservation date is May 17th, 2019,the preservation organization is China General Microbiological Culture Collection Center, and a 16SrRNA gene sequence of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is shown in SEQ ID NO:1 as shown in the description. A separation method of the fusobacterium nucleatum subsp.animalis strain is provided. A result of co-culture of a colorectal cancer cell line and the THCT5A4 shows that the THCT5A4 can significantly promote proliferation of colorectal cancer cells, therefore, the THCT5A4 can provide diverse in-vitro or in-vivo experimental conditions for simulating an intestinal environment for studies of colorectal cancer, and a colorectal cancer disease model can be built for screening medicines for treating colorectal cancer.

The invention provides a fusobacterium nucleatum polymorphic subspecies isolate THCT15E1, a classification name is Fusobacterium nuucleates subsp.nucleatum THCT15E1, a preservation number of the strain is CCTCC NO: M 2019362, a preservation date is May 17, 2019, a preservation unit is China Center for Type Culture Collection, and the 16SrRNA gene sequence of the strain is shown as SEQ ID NO: 1. The result of co-culture of the colorectal cancer cell line and THCT15E1 shows that THCT15E1 can significantly promote colorectal cancer cell proliferation; therefore, the THCT15E1 can provide diversified experimental conditions for in-vitro or in-vivo intestinal environment simulation for colorectal cancer research, and can also construct a colorectal cancer disease model to screen drugs for treating colorectal cancer.

The invention provides fusobacterium nucleatum THCT14E2 which is obtained from large intestine cancer tumor tissue and does not belong to known fusobacterium nucleatum subsp.vincentii. The 16SrRNA gene sequence of the strain is as shown in SEQID NO:1. The classification designation of the THCT14E2 is Fusobacterium nucleatum, the preservation number is CCTCC NO:M 2019361, the preservation date is May 17th, 2019, and the preservation unit is China Center for Type Culture Collection. The colorectal cancer cell line and THCT14E2 co-culture result shows that the THCT14E2 can significantly promote colorectal cancer cell proliferation. Therefore, the THCT14E2 can promote understanding of micro-ecology diversity of rectum cancer, and facilitate function research of the fusobacterium nucleatum fromthe colorectal cancer.

The invention discloses a constant-temperature detecting method for fusobacterium nucleatum, as well as a special primer and a kit thereof. The invention provides a circular mediate constant-temperature amplification primer for detecting the fusobacterium nucleatum, which is composed of a primer 1, a primer 2, a primer 3, a primer 4 and a primer 5, wherein the sequence 2, sequence 3, sequence 4, sequence 5 and sequence 6 in a sequence table are respectively taken as the nucleotide sequences of the primer 1, the primer 2, the primer 3, the primer 4 and the primer 5. According to the constant-temperature detecting method provided by the invention, the fusobacterium nucleatum can be quickly, conveniently, efficiently, high-peculiarly and high-sensitively detected under a constant temperature condition; no complex instrument is required; a new technical platform is supplied for detecting the fusobacterium nucleatum; the constant-temperature detecting method can be used for screening and detecting the fusobacterium nucleatum for the basic medical treatment enterprises and various disease control and prevention centers; the constant-temperature detecting method has wide market prospect, has higher economic and social benefits and is suitable for wide-scope popularization and application.

The invention provides a lactobacillus plantarum LN66 and an application thereof to a product reducing a halitosis risk and relates to the technical field of halitosis prevention and treatment. An LN66 strain is preserved with the number of CGMCC No. 17369. The LN66 strain is directly separated from a healthy human body, is a Gram staining positive bacillus, is incapable of generating spores and is capable of growing in both aerobiotic and anaerobic environments. The LN66 strain has good tolerance to lysozyme and adapts to the oral environment, not aims at killing fusobacterium nucleatum, butaims at reducing the occurrence and development risks of halitosis by reducing the expression level of genes relevant to the formation of a biological film in the fusobacterium nucleatum, reducing thesecretion of extracellular polymeric substances (EPSs) of the fusobacterium nucleatum and specifically inhibiting or reducing the formation of fusobacterium nucleatum biological films.

The invention provides a primer compound for identifying intestinal microecological state and an application thereof. The primer compound is a specific primer designed for intestinal bacterium 16S rRNA; the specific primer includes random basic groups; the quantity of random basic groups is 3-5; the intestinal bacterium includes any one of or combination of at least two of symbiotic clostridia, bifidobacterium adolescentis, fusobacterium nucleatum, peptostreptococcus anaerobius or klebsiella. A kit researched and developed on the basis of the primer compound provided by the invention has a specificity for detecting intestinal microecological imbalance reaching up to 92.5% and a sensitivity reaching up to 80.43%.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The invention relates to a preparation containing Fusobacterium nucleatum and PD-L1 antibody and used for immunotherapy of colorectal cancer, application of the preparation, a Fusobacterium nucleatummarker to predict curative effect of PD-L1 antibody therapy of colorectal cancer, and application of the marker. The influence of Fusobacterium nucleatum upon PD-L1 antibody immunotherapy of colorectal cancer is studied deeply herein, and it is discovered that PD-L1 monoclonal antibody therapy is more effective to colorectal cancer in the presence of Fusobacterium nucleatum, while PD-L1 monoclonalantibody therapy helps evidently extend the lifetime of a mouse with colorectal cancer in the presence of Fusobacterium nucleatum; by discussing the mechanism of Fusobacterium nucleatum, it is discovered that Fusobacterium nucleatum can provide transcriptional control for the expression of PD-L1; after PD-L1 antibody therapy is carried out for colorectal cancer tissues in the presence of Fusobacterium nucleatum, the proportion of CD8 positive T cells is increased; all these above are good for the effect of PD-L1 antibody therapy. It is indicated that the presence or absence of Fusobacterium nucleatum is suitable for acting as a potential marker to judge the curative effect of PD-L1 monoclonal antibody therapy for the patient with colorectal cancer; Fusobacterium nucleatum and PD-L1 monoclonal antibody can form an immunotherapy preparation for patients with colorectal cancer.

The invention provides a bergenia crassifolia extract and an extracting method and medical application in oral diseases. Through a resazurin dyeing method and an XTT method, the extract of bergenia crassifolia is subjected to bacteriostatic activity and inhibitory biological film activity study, the extract of bergenia crassifolia has an obvious inhibitory effect on streptococcus mutans, streptococcus sanguis, streptococcus salivarius, lactobacillus acidophilus, porphyromonas gingivalis, fusobacterium nucleatum, actinobacillus actinomycetemcomitan and biological film of the fungi, has a better inhibitory effect on streptococcus mutans, porphyromonas gingivalis and the biological film of the fungi and can be used for preparing daily necessities and medicine for preventing and treating the oral diseases.

The invention particularly discloses Lactiplantibacillus plantarum HNU082 with an antagonistic effect and application thereof. The strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on March 9, 2021, the preservation number is GDMCC NO 61552: and the preservation address is the 5 floor, Laboratory Building of the Institute of Microbiology, #100, Middle Xianlie Road, Guangzhou City, China; and the taxonomic name is Lactiplantibacillus plantarum. According to the Lactiplantibacillus plantarum HNU082 disclosed by the invention, one strain of Lactiplantibacillus plantarum HNU082 is screened from a lot of samples; the strain has a relatively good antagonistic effect on Fusobacterium nucleatum in vitro or in vivo; furthermore, the Lactiplantibacillus plantarum HNU082 can be used for inducing the generation of anti-inflammatory cytokines and enhancing intestinal and systemic immune responses; the growth of pathogenic bacteria is inhibited through reducing the pH (potential of Hydrogen) value and the content of short-chain fatty acid is increased, so that the expression of inflammatory factors is reduced; and a feasible intervention strategy is provided for in-vivo antagonism of probiotics on the Fusobacterium nucleatum and a reliable basis is provided for preventing early-stage colorectal cancer.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and / or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The present disclosure relates to a Fusobacterium nucleatum FomA protein vaccine, a preparation method and applications thereof. The preparation method comprises: linking a signal-peptide-sequence-deleted FomA gene linked to a MBP tag to an expression vector, transforming into Escherichia coli, carrying out induced expression, carrying out affinity purification on FomA recombinant protein by usingAmylose Resin High Flow, and carrying out enzyme digestion with a tev enzyme to remove the MBP tag to obtain the Fusobacterium nucleatum FomA protein vaccine. According to the present invention, theFusobacterium nucleatum FomA protein vaccine has good stability, and can effectively improve the immunity of organisms to Fusobacterium nucleatum, improve the survival rate and delay the occurrence and development of colons tumor; and in APCMin / + mice models, the FomA protein vaccine has significant protecting effect on the mice, can be used as a new colon tumor vaccine candidate, and has great application prospects.

The invention provides an oral spray used for daily oral health maintenance and a preparation method of the oral spray. The oral spray is prepared from the following raw materials: epigallocatechin gallate, procyanidine, erythritol, propolis extract, notoginsenoside R1, menthol, lactitol, alcohol and sterile water. The oral spray prepared by adopting the method provided by the invention has the clearing and the obvious inhibiting effects for various main pathogenic bacteria of the oral cavity, including fusobacterium nucleatum, porphyromonas gingivalis and the like, has the obvious inflammation-diminishing efficacy for various inflammations of the oral cavity, is beneficial for the wound healing of the oral cavity, and can reduce gum bleeding and the like.

The invention discloses a kit for detecting colorectal cancer indicator bacteria. The kit is characterized by comprising the following components: a specific primer combination for identifying the indicator bacteria, wherein the primer combination is shown as SEQ ID NO. 1-14, and the indicator bacteria are the combination of fusobacterium nucleatum (F.nucleolus), anaerobic digestion streptococcus(P.anaerobicus), clostridium symbiosum (C.symbiolum), Porphyromonas saccharolytica (P.asaccharolytica), Prevotella intermedia (P.intermedia), Bacteroides fragilis (B.fragilis) and Streptococcus salivarius (S.salivarius). The kit for detecting colorectal cancer indicator bacteria disclosed by the invention has the beneficial effects that the colorectal cancer can be identified only by collecting astool sample. The principle is that the aim of identifying the colorectal cancer by detecting the colorectal cancer pathogenic bacteria in excrement, the sensitivity can reach 92.9%, and the specificity is 92.6%.